RxDoctor Payments Data

Syed Abid, MD

Hematology & Oncology · St Petersburg, FLNPI 1013902006

Payments from drug & device makers

$17,171in general payments, 2019–2025

Across 817 payments — averaging $21.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • Merck$1K
  • Pfizer$1K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Daiichi Sankyo Inc.$768
  • AstraZeneca$617
  • plus $10K from 54 others

What the payments were for

  • Food & beverage$16,13794%
  • Education$1,0346%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis109$1,958
Merck67$1,396
Pfizer64$1,244
E.r. Squibb & Sons, L.L.C.63$1,164
Daiichi Sankyo Inc.30$768
AstraZeneca18$617
Seagen Inc.26$606
Gilead(2 entities)27$566
Bristol Myers Squibb26$538
Johnson & Johnson(2 entities)28$532
Astellas Pharma US Inc19$529
GSK19$510
Incyte Corporation21$483
Exelixis Inc.28$436
Amgen25$419
Takeda Pharmaceuticals U.S.A., Inc.15$409
AbbVie20$394
Regeneron Healthcare Solutions, Inc.13$370
Sanofi15$319
Array Biopharma Inc11$257
Beigene USA, Inc.8$252
Genentech USA, Inc.12$251
Lilly USA, LLC12$233
Boehringer Ingelheim11$223
Stemline Therapeutics Inc.6$153
Karyopharm Therapeutics Inc.8$144
Puma Biotechnology, Inc.7$135
Tempus AI, Inc6$132
Tersera Therapeutics LLC7$125
Mirati Therapeutics, Inc.6$113
Celltrion USA Inc.1$112
Eisai Inc.5$99
Fennec Pharmaceuticals, Inc.4$99
Pharmacyclics LLC, An Abbvie Company4$84
Ipsen Biopharmaceuticals, Inc5$84
AVEO Pharmaceuticals, Inc.4$75
Jazz Pharmaceuticals Inc.3$64
Taiho Oncology, Inc.3$56
Rigel Pharmaceuticals, Inc.3$56
Acrotech Biopharma Inc.4$53
Beone Medicines USA, Inc.2$51
Caris MPI, Inc.2$51
Genmab U.S., Inc.2$50
Bayer2$46
AMAG Pharmaceuticals, Inc.2$43
Verity Pharmaceuticals Inc.3$42
Legend Biotech USA Inc.1$41
CTI Biopharma Corp.2$39
Sobi, Inc1$39
Agios Pharmaceuticals, Inc.2$37
Sun Pharmaceutical Industries Inc.2$36
Partner Therapeutics, Inc.2$35
Foundation Medicine, Inc.1$35
Sumitomo Pharma America, Inc.2$34
Pharmaessentia USA Corporation1$34
Dova Pharmaceuticals2$32
Immunocore Limited1$32
Novo Nordisk2$30
Geron Corporation1$26
Heron Therapeutics, Inc.2$26

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,171 in reported general payments places this provider in the 50th percentile of 694 hematology & oncology providers in Florida.

See all hematology & oncology providers in Florida

Medicare billing

Part B allowed, 2024
$905,774
Medicare patients
179
Services billed
66,729

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib42$810,826
ErleadaApalutamide54$792,724
IbrancePalbociclib31$485,468
XtandiEnzalutamide36$464,515
Lenalidomide29$430,309
TecentriqAtezolizumab38$394,289
ProcritEpoetin Alfa100$380,157
Darzalex FasproDaratumumab-Hyaluronidase-Fihj36$332,183
CalquenceAcalabrutinib Maleate21$315,220
PromactaEltrombopag Olamine22$284,838
RevlimidLenalidomide16$247,102
VenclextaVenetoclax19$212,467
JakafiRuxolitinib Phosphate12$207,555
RetacritEpoetin Alfa-Epbx115$164,956
KeytrudaPembrolizumab12$139,920

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada, Procrit, Remicade$532$1,241,743165 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$84$810,82642 claims
PfizerIbrance, Retacrit, Ruxience, Nivestym, Eliquis$1,244$768,095197 claims
Astellas Pharma US IncXtandi$529$464,51536 claims
NovartisPromacta, Gleevec$1,958$387,82135 claims
AstraZenecaCalquence$617$315,22021 claims
Bristol Myers SquibbRevlimid, Abraxane$538$291,65931 claims
AbbVieVenclexta, Lupron Depot$394$263,52839 claims
AmgenXgeva, Riabni, Prolia$419$252,07077 claims
Incyte CorporationJakafi$483$207,55512 claims
MerckKeytruda$1,396$139,92012 claims
Regeneron Healthcare Solutions, Inc.Libtayo$370$134,40014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 694 hematology & oncology providers in Florida.

Other hematology & oncology in St Petersburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →